Diabodies: Molecular engineering and therapeutic applications

Drug News and Perspectives

Volumn 22, Issue 8, 2009, Pages 453-458

  Wu, Chengbin ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; BLINATUMOMAB; CATUMAXOMAB; CD30 DIABODY; CERTOLIZUMAB PEGOL; DIABODY; ESBA 105; INFLIXIMAB; MT 103; SCDB DIABODY; SCDB FC DIABODY; TANDAB; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ANTIBODY PRODUCTION; ANTIGEN BINDING; ANTIGEN RECOGNITION; AREA UNDER THE CURVE; ASCITES; CANCER CELL DESTRUCTION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CARCINOMA; CONTINUOUS INFUSION; CROHN DISEASE; CROSS LINKING; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG HALF LIFE; DRUG PENETRATION; DRUG RESEARCH; DRUG STABILITY; EFFECTOR CELL; GLYCOSYLATION; HEMATOLOGIC MALIGNANCY; HUMAN; LOW DRUG DOSE; LYMPHOCYTOTOXICITY; NONHUMAN; PROTEIN ENGINEERING; PROTEIN MODIFICATION; PROTEIN STABILITY; REVIEW; TARGET CELL; TARGET CELL DESTRUCTION;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; PROTEIN ENGINEERING; T-LYMPHOCYTES;

EID: 76049090707     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2009.22.8.1413783     Document Type: Review

References (58)

1. Holliger, P., Prospero, T. and Winter, G. "Diabodies": Small bivalent and bispecific anti-body fragments. Natl Acad Sci U S A 1993, 90(14): 6444-8.
2. Kipriyanov, S.M., Moldenhauer, G., Schuhmacher, J. et al. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J Mol Biol 1999, 293(1): 41-56.
3. Alt, M., Muller, R. and Kontermann, R.E. Novel tetravalent and bispecific IgG-like anti-body molecules combining single-chain diabodies with the immunoglobulin gamma1 Fc or CH3 region. FEBS Lett 1999, 454(1-2): 90-4.
4. Lu, D., Jimenez, X., Zhang, H. et al. Di-dia body: A novel tetravalent bispecific antibody molecule by design. J Immunol Methods 2003, 279(1-2): 219-32.
5. Lu, D., Zhang, H., Koo, H. et al. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem 2005, 280(20): 19665-72.
6. Li, Y., Li, H., Smith-Gill, S.J. and Mariuzza, R.A. Three-dimensional structures of the free and antigen-bound Fab from monoclonal antilysozyme antibody HyHEL-63. Biochemistry 2000, 39(21): 6296-309.
7. Padlan, E.A. Anatomy of the antibody molecule. Mol Immunol 1994, 31(3): 169-217.
8. Huang, B.C., Foote, L.J., Lankford, T.K., Davern, S.M., McKeown, C.K. and Kennel, S.J. A diabody that dissociates to monomer forms at low concentration: Effects on binding activity and tumor targeting. Biochem Biophys Res Commun 2005, 327(4): 999-1005.
9. Zhu, Z., Presta, L. G., Zapata, G. and Carter, P. Remodeling domain interfaces to enhance heterodimer formation. Protein Sci 1997, 6(4): 781-8.
10. FitzGerald, K., Holliger, P. and Winter, G. Improved tumour targeting by disulphide stabilized diabodies expressed in Pichia pastoris. Protein Eng 1997,10(10): 1221-5.
11. Gao, Y., Xiong, D., Yang, M. et al. Efficient inhi bition of multidrug-resistant human tumors with a recombinant bispecific anti-P-glycoprotein x anti-CD3 diabody. Leukemia 2004, 18(3): 513-20.
12. Worn, A. and Pluckthun, A. Different equilibri um stability behavior of ScFv fragments: Identification, classification, and improvement by protein engineering. Biochemistry 1999, 38(27): 8739-50.
13. Young, N.M., MacKenzie, C.R., Narang, S.A., Oomen, R.P. and Baenziger, J.E. Thermal sta bilization of a single-chain Fv antibody fragment by introduction of a disulphide bond. FEBS Lett 1995, 377(2): 135-9.
14. Asano, R., Kudo, T., Nishimura, Y. et al. Efficient construction of a diabody using a refolding system: Anti-corcinoembryonic antigen recombinant antibody fragment. J Biochem 2002, 132(6): 903-9.
15. Jermutus, L., Honegger, A., Schwesinger, F., Hanes, J. and Pluckthun, A. Tailoring in vitro evolution for protein affinity or stability. Proc Natl Acad Sd U S A 2001, 98(1): 75-80.
16. Jung, S., Honegger, A. and Pluckthun, A. Selection for improved protein stability by phage display. J Mol Biol 1999, 294(1): 163-80.
17. Sieber, V., Pluckthun, A. and Schmid, F.X. Selecting proteins with improved stability by a phage-based method. Nat Biotechnol 1998, 16(10): 955-60.
18. Ewert, S., Honegger, A. and Pluckthun, A. Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering. Methods 2004, 34(2): 184-99.
19. Worn, A. and Pluckthun, A. An intrinsically stable antibody scFv fragment can tolerate the loss of both disulfide bonds and fold correctly. FEBS Lett 1998, 427(3): 357-61.
20. Worn, A., Auf der Maur, A., Escher, D., Honegger, A., Barberis, A. and Pluckthun, A. Correlation between in vitro stability and in vivo performance of anti-GCN4 intrabodies as cytoplasmic inhibitors. J Biol Chem 2000, 275(4): 2795-803.
21. Auf der Maur, A., Escher, D. and Barberis, A. Antigen-independent selection of stable intracellular single-chain antibodies. FEBS Lett 2001, 508(3): 407-12.
22. Auf der Maur, A., Tissot, K. and Barberis, A. Antigen-independent selection of intracellular stable antibody frameworks. Methods 2004, 34(2): 215-24.
23. Furrer, E., Berdugo, M., Stella, C. et al. Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye. Invest Ophthalmol Vis Sci 2009, 50(2): 771-8.
24. Ottiger, M., Thiel, M.A., Feige, U., Lichtlen, P. and Urech, D.M. Efficient intraocular penetra tion of topical anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer. Invest Ophthalmol Vis Sci 2009, 50(2): 779-86.
25. Urech, D.M., Feige, U., Ewert, S. et al. Anti- inflammatory and cartilage-protecting effects of an intra-articularly injected anti-TNF-α scFv (ESBA105) designed for local therapeutic use. Ann Rheum Dis 2009. Epub ahead of print.
26. Chapman, A.P. PEGylated antibodies and antibody fragments for improved therapy: A review. Adv Drug Deliv Rev 2002, 54(4): 531-45.
27. Melmed, G.Y., Targan, S.R., Yasothan, U., Hanicq, D. and Kirkpatrick, P. Certolizumab pegol. Nat Rev Drug Discov 2008, 7(8): 641-2.
28. Li, L., Yazaki, P.J. anderson, A.L. et al. Improved biodistribution and radioimmuno-imaging with poly(ethylene glycol)-DOTA-conjugated anti-CEA diabody. Bioconjug Chem 2006, 17(1): 68-76.
29. Stork, R., Zettlitz, K.A., Muller, D., Rether, M., Hanisch, F.G. and Kontermann, R.E. N-glyco sylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies. J Biol Chem 2008, 283(12): 7804-12.
30. Junghans, R.P. and Anderson, C.L. The pro tection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci U S A 1996, 93(11): 5512-6.
31. Muller, D., Karle, A., Meissburger, B., Hofig, I., Stork, R. and Kontermann, R.E. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J Biol Chem 2007, 282(17): 12650-60.
32. Stork, R., Muller, D. and Kontermann, R.E. A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G. Protein Eng Des Sel 2007, 20(11): 569-76.
33. Asano, R., Kawaguchi, H., Watanabe, Y. et al. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells. J lmmunother 2008, 31(8): 752-61.
34. Adams, G.P., Shaller, C.C., Dadachova, E. et al. A single treatment of yttrium-90-labeled CHX-A″-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Cancer Res 2004, 64(17): 6200-6.
35. Shimazaki, K., Lepin, E.J., Wei, B. et al. Diabodies targeting epithelial membrane protein 2 reduce tumorigenicity of human endometrial cancer cell lines. Clin Cancer Res 2008, 14(22): 7367-77.
36. Ackerman, M.E., Pawlowski, D. and Wittrup, K.D. Effect of antigen turnover rote and expres sion level on antibody penetration into tumor spheroids. Mol Cancer Ther 2008,7(7): 2233-40.
37. Thurber, G.M., Schmidt, M.M. and Wittrup, K.D. Factors determining antibody distribution in tumors. Trends Pharmacol Sci 2008, 29(2): 57-61.
38. Beckman, R.A., Weiner, L.M. and Davis, H.M. Antibody constructs in cancer therapy: Protein engineering strategies to improve exposure in solid tumors. Cancer 2007, 109(2): 170-9.
39. Colcher, D., Pavlinkova, G., Beresford, G., Booth, B.J., Choudhury, A. and Batra, S.K. Pharmacokinetics and biodistribution of genetically- engineered antibodies. Q J Nucl Med 1998, 42(4): 225-41.
40. Wu, A.M. and Yazaki, P.J. Designer genes: Recombinant antibody fragments for biological imaging. Q J Nucl Med 2000, 44(3): 268-83.
41. Robinson, M.K., Shaller, C., Garmestani, K. et al. Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies. Clin Cancer Res 2008, 14(3): 875-82.
42. Kim, K.M., McDonagh, C.F., Westendorf, L. et al. Anti-CD30 diabody-drug conjugates with potent antitumor activity. Mol Cancer Ther 2008, 7(8): 2486-97.
43. Shen, J. and Zhu, Z. Anti-CD30 diabody-drug conjugates with potent antitumor activity. Curr Opin Mol Ther 2008, 10(3): 273-84.
44. Duval, M., Posner, M.R. and Cavacini, L.A. A bispecific antibody composed of a nonneutralizing antibody to the gp41 immunodominant region and an anti-CD89 antibody directs broad human immunodeficiency virus destruction by neutrophils. J Virol 2008, 82(9): 4671-4.
45. Kontermann, R.E. Recombinant bispecific antibodies for cancer therapy. Acta Pharmacol Sin 2005, 26(1): 1-9.
46. Muller, D. and Kontermann, R.E. Recombinant bispecific antibodies for cellular cancer immunotherapy. Curr Opin Mol Ther 2007, 9(4): 319-26.
47. Kontermann, R.E., Wing, M.G. and Winter, G. Complement recruitment using bispecific diabodies. Nat Biotechnol 1997, 15(7): 629-31.
48. Kashentseva, E.A., Douglas, J.T., Zinn, K.R., Curiel, D.T. and Dmitriev, I.P. Targeting of ade novirus serotype 5 pseudotyped with short fiber from serotype 41 to c-erbB2-positive cells using bispecific single-chain diabody. J Mol Biol 2009, 388(3): 443-61.
49. Muller, K.M., Arndt, K.M., Strittmatter, W. and Pluckthun, A. The first constant domain (C(H)1 and C(L)) of on antibody used as heterodimerization domain for bispecific miniantibodies. FEBS Lett 1998, 422(2): 259-64.
50. Nettelbeck, D.M., Miller, D.W., Jerome, V. et al. Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105). Mol Ther 2001, 3(6): 882-91.
51. Buhler, P., Wolf, P., Gierschner, D. et al. A bis pecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells. Cancer Immunol lmmunother 2008, 57(1): 43-52.
52. Hayashi, H., Asano, R., Tsumoto, K. et al. A highly effective and stable bispecific diabody for cancer immunotherapy: Cure of xenografted tumors by bispecific diabody and T-LAK cells. Cancer Immunol lmmunother 2004, 53(6): 497-509.
53. Liu, F., Chen, Z., Jiang, W., Yang, C., Xiong, D. and Zhu, Z. Improvement in soluble expression levels of a diabody by exchanging expression vectors. Protein Expr Purif 2008, 62(1): 15-20.
54. Liu, J., Yang, M., Wang, J. et al. Improvement of tumor targeting and antitumor activity by a disulphide bond stabilized diabody expressed in Escherichia coli. Cancer Immunol lmmunother 2009, 58(11): 1761-9.
55. Nagorsen, D., Bargou, R., Ruttinger, D., Kufer, P., Baeuerle, P.A. and Zugmaier, G. Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab. Leuk Lymphoma 2009, 50(6): 1-6.
56. Haas, C., Krinner, E., Brischwein, K. et al. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology 2009, 214(6): 441-53.
57. Bargou, R., Leo, E., Zugmaier, G. et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008, 321(5891): 974-7.
58. Perisic, O., Webb, P.A., Holliger, P., Winter, G. and Williams, R.L. Crystal structure of a dia body, a bivalent antibody fragment. Structure 1994, 2(12): 1217-26.